December 7, 2020 -- Guardant Health has touted research presented at the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) demonstrating how its tools benefit women with breast cancer and advance breast cancer research.
Three research abstracts presented at the conference utilized Guardant's technology:
In particular, the company pointed to the new research showing its GuardantInform platform identified treatment resistance in some patients with metastatic breast cancer. GuarantInform is a clinical-genomic platform designed to support more effective cancer therapies by combining de-identified clinical information with genomic data from the Guardant360 liquid biopsy test, according to Guardant.
The new research utilizing the platform showed patients with estrogen-receptor positive (ER-positive) and HER-2 negative metastatic breast cancer experienced treatment resistance. The tool can also be used targeted drug development, clinical trial optimization, and postmarketing studies, Guardant noted.